Dose optimization during drug development: whether and when to optimize
JNCI: Journal of the National Cancer Institute · 08.05.2023 · 115 (5) · 492-497
DOI: 10.1093/jnci/djac232 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 19.12.2022. Verfasst von Edward L Korn und 2 weiteren Autor:innen. Beteiligte Einrichtung: Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Research Design, Drug Development. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The goal of dose optimization during drug development is to identify a dose that preserves clinical benefit with optimal tolerability. Traditionally, the maximum tolerated dose in a small phase I dose escalation study is used in the phase II trial assessing clinical activity of the agent. Although it is possible that this dose level could be altered in the phase II trial if an unexpected level of toxicity is seen, no formal dose optimization has routinely been incorporated into later stages of drug development. Recently it has been suggested that formal dose optimization (involving randomly assigning patients between 2 or more dose levels) be routinely performed early in drug development, even before it is known that the experimental therapy has any clinical activity at any dose level. We consider the relative merits of performing dose optimization earlier vs later in the drug development process and demonstrate that a considerable number of patients may be exposed to ineffective therapies unless dose optimization is delayed until after clinical activity or benefit of the new agent has been established. We conclude that patient and public health interests may be better served by conducting dose optimization after (or during) phase III evaluation, with some exceptions when dose optimization should be performed after activity shown in phase II evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
- Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
ORCID-Profile: Edward L Korn, Boris Freidlin
Zitieren
APA
Korn, E. L., Moscow, J. A., & Freidlin, B. (2023). Dose optimization during drug development: whether and when to optimize. JNCI: Journal of the National Cancer Institute, 115(5), 492-497. https://doi.org/10.1093/jnci/djac232
Vancouver
Korn EL, Moscow JA, Freidlin B. Dose optimization during drug development: whether and when to optimize. JNCI: Journal of the National Cancer Institute. 2023;115(5):492-497. doi:10.1093/jnci/djac232
BibTeX
@article{Korn2023,
author = {Korn, Edward L and Moscow, Jeffrey A and Freidlin, Boris},
title = {Dose optimization during drug development: whether and when to optimize},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2023},
volume = {115},
number = {5},
pages = {492--497},
doi = {10.1093/jnci/djac232}
}
EUVIMED